| Open |
S2104 |
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |
10/14/2021 |
|
28% |
|
|
| Closed |
S2011 |
SWOG GAPTrial |
10/6/2021 |
11/15/2023 |
3% |
|
|
| Closed |
S1934 |
NASSIST |
9/9/2021 |
3/1/2023 |
0% |
|
|
| Open |
S2013 |
I-CHECKIT |
8/16/2021 |
|
100% |
|
|
| Open |
S1912CD |
CREDIT |
7/26/2021 |
|
71% |
|
|
| Open |
S2005 |
A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) |
6/24/2021 |
|
3% |
|
|
| Open |
S1900E |
LUNGMAP S1900E: KRAS Targeted Therapy Sub-Study |
4/2/2021 |
|
97% |
|
|
| Open |
S1918 |
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL |
3/19/2021 |
|
23% |
|
|
| Open |
S1937 |
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for,… |
2/16/2021 |
|
15% |
|
|
| Open |
S2007 |
Sacituzumab Govitecan for HER2-Neg Breast Cancer and Brain Metastases |
12/15/2020 |
|
55% |
|
|
| Open |
S1925 |
EVOLVE CLL |
12/14/2020 |
|
41% |
|
|
| Open |
S2001 |
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects |
12/4/2020 |
|
55% |
|
|
| Open |
S1931 |
PROBE trial |
11/16/2020 |
|
28% |
|
|
| Open |
S2000 |
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases |
9/23/2020 |
|
91% |
|
|
| Open |
S1904 |
Decision Support Tool |
9/1/2020 |
|
96% |
|
|
| Open |
S1905 |
PI/II OBI-3424 for R/R T-ALL/T-LBL |
8/17/2020 |
|
22% |
|
|
| Open |
S1933 |
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status |
6/15/2020 |
|
77% |
|
|
| Closed |
S1929 |
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC) |
6/15/2020 |
12/15/2022 |
100% |
|
|
| Open |
S1823 |
miRNA 371 Study in Germ Cell Tumors |
6/1/2020 |
|
99% |
|
|
| Open |
S1914 |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC |
3/25/2020 |
|
73% |
|
|
